PURPOSE: Catheter ablation for paroxysmal atrial fibrillation (PAF) is an effective treatment. Favourable outcomes at 6-12 months post-ablation have been reported using the multi-electrode catheter 'pulmonary vein ablation catheter (PVAC)' but little is known about longer term outcomes. There are also limited data on quality of life (QoL) post-atrial fibrillation (AF) ablation beyond 2 years of follow-up. METHODS: Two hundred three consecutive patients (77 % male, mean age 57.7 ± 11 years) who had a PAF ablation were included. Patients underwent conventional pulmonary vein isolation (PVI) (n = 128) or PVAC ablation (n = 75). Patients' symptoms were scored at baseline, at clinic follow-up and on questionnaire follow-up using the validated Canadian Cardiovascular Society Severity of AF (CCS-SAF) scale. The 'AF Effect on QualiTy of life' (AFEQT) questionnaire was used on questionnaire follow-up. RESULTS: Mean questionnaire follow-up was 854 ± 176 days with 74 % response rate. The majority of patients (91.6 % overall) were highly symptomatic at baseline with CCS-SAF class 3 or 4 symptoms. CCS-SAF class on follow-up questionnaire decreased significantly from baseline for both groups (mean 1.69 ± 1.7 for PVAC and 1.45 ± 1.5 for PVI, p = 0.001 and p < 0.001, respectively) with no difference between groups (p = 0.52) and the majority being class 0 or 1 (59.9 % overall). Mean AFEQT questionnaire scores were similar between both groups (78.1 ± 25 vs. 82 ± 23, p = 0.35). Total procedure time was significantly shorter in the PVAC group (135 ± 54 vs. 178 ± 43 min, p < 0.001). CONCLUSION: There was a comparable and significant improvement in QoL post-ablation in patients who underwent ablation using PVAC catheter and conventional techniques.
PURPOSE: Catheter ablation for paroxysmal atrial fibrillation (PAF) is an effective treatment. Favourable outcomes at 6-12 months post-ablation have been reported using the multi-electrode catheter 'pulmonary vein ablation catheter (PVAC)' but little is known about longer term outcomes. There are also limited data on quality of life (QoL) post-atrial fibrillation (AF) ablation beyond 2 years of follow-up. METHODS: Two hundred three consecutive patients (77 % male, mean age 57.7 ± 11 years) who had a PAF ablation were included. Patients underwent conventional pulmonary vein isolation (PVI) (n = 128) or PVAC ablation (n = 75). Patients' symptoms were scored at baseline, at clinic follow-up and on questionnaire follow-up using the validated Canadian Cardiovascular Society Severity of AF (CCS-SAF) scale. The 'AF Effect on QualiTy of life' (AFEQT) questionnaire was used on questionnaire follow-up. RESULTS: Mean questionnaire follow-up was 854 ± 176 days with 74 % response rate. The majority of patients (91.6 % overall) were highly symptomatic at baseline with CCS-SAF class 3 or 4 symptoms. CCS-SAF class on follow-up questionnaire decreased significantly from baseline for both groups (mean 1.69 ± 1.7 for PVAC and 1.45 ± 1.5 for PVI, p = 0.001 and p < 0.001, respectively) with no difference between groups (p = 0.52) and the majority being class 0 or 1 (59.9 % overall). Mean AFEQT questionnaire scores were similar between both groups (78.1 ± 25 vs. 82 ± 23, p = 0.35). Total procedure time was significantly shorter in the PVAC group (135 ± 54 vs. 178 ± 43 min, p < 0.001). CONCLUSION: There was a comparable and significant improvement in QoL post-ablation in patients who underwent ablation using PVAC catheter and conventional techniques.
Authors: Anil K Gehi; Samuel Sears; Neeta Goli; T Jennifer Walker; Eugene Chung; Jennifer Schwartz; Kathryn A Wood; Kimberly Guise; J Paul Mounsey Journal: J Cardiovasc Electrophysiol Date: 2012-03-19
Authors: R J Hunter; T J Berriman; I Diab; V Baker; M Finlay; L Richmond; E Duncan; R Kamdar; G Thomas; D Abrams; M Dhinoja; S Sporton; M J Earley; R J Schilling Journal: Heart Date: 2010-05-18 Impact factor: 5.994
Authors: Louise S Jenkins; Michael Brodsky; Eleanor Schron; Mina Chung; Thomas Rocco; Ellis Lader; Martha Constantine; Robert Sheppard; Donald Holmes; Donna Mateski; Liz Floden; Marilyn Prasun; H Leon Greene; Lynn Shemanski Journal: Am Heart J Date: 2005-01 Impact factor: 4.749
Authors: María J Marquine; Deborah K Attix; Larry B Goldstein; Gregory P Samsa; Martha E Payne; Gordon J Chelune; David C Steffens Journal: Stroke Date: 2010-07-22 Impact factor: 7.914
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: Allan Bohm; Lubos Urban; Lubomira Tothova; Ljuba Bacharova; Peter Musil; Jan Kyselovic; Peter Michalek; Tomas Uher; Branislav Bezak; Peter Olejnik; Robert Hatala Journal: J Interv Card Electrophysiol Date: 2021-03-10 Impact factor: 1.900